Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 10% IN PLASTIC CONTAINER vs DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Intravenous dextrose provides a source of calories and water for hydration. Dextrose is metabolized to carbon dioxide and water, yielding energy (approximately 3.4 kcal/g). It also stimulates insulin secretion and promotes glycogen synthesis.
Dextrose is a monosaccharide that provides a source of calories and fluid for parenteral nutrition. It increases blood glucose levels and is metabolized to carbon dioxide and water, providing energy. It also serves as a source of water for hydration.
Intravenous infusion as a source of calories and fluid for patients requiring parenteral nutrition,Treatment of hypoglycemia,Fluid and electrolyte maintenance,Diluent for compatible medications
Intravenous infusion for parenteral nutrition when oral intake is inadequate,Treatment of hypoglycemia,Fluid resuscitation in dehydrated patients,As a vehicle for intravenous drug delivery
Intravenous infusion, 500-1000 m L (50-100 g dextrose) as a single dose, rate determined by clinical condition; typical maintenance 100-125 m L/h.
Intravenous infusion: 500-1000 m L as needed based on fluid and caloric requirements. Typical rate: 100-200 m L/hour for maintenance. Maximum infusion rate: 0.5-0.8 g/kg/hour.
The metabolic half-life of glucose is 1.5–2.5 hours; however, the plasma half-life of infused dextrose is approximately 1.5–2 hours, with clinical context indicating that doses >0.5 g/kg/hour can exceed oxidative capacity, leading to hyperglycemia.
Intravenous: 1.5-2.5 hours for glucose clearance; prolonged in renal impairment or diabetes mellitus
Dextrose is metabolized via glycolysis, the citric acid cycle, and oxidative phosphorylation to produce ATP, carbon dioxide, and water. Insulin facilitates cellular uptake and metabolism. Excess glucose is stored as glycogen in liver and muscle, or converted to fat via lipogenesis.
Dextrose is metabolized via glycolysis and subsequently enters the citric acid cycle (Krebs cycle) to produce ATP. It is also stored as glycogen in the liver and muscles.
Glucose is primarily metabolized via glycolysis and oxidative phosphorylation to CO2 and water; less than 5% is excreted unchanged in urine under normal conditions. In hyperglycemia with glycosuria, up to 50% may be lost renally.
Renal: negligible as unchanged drug; metabolized to water and carbon dioxide, excreted via lungs (>90%) and urine (glucose normally <0.1%)
Glucose is not significantly bound to plasma proteins (<10%); it is freely diffusible.
Negligible (<5%); not bound to plasma proteins
Approximately 0.2 L/kg (total body water), reflecting distribution into extracellular and intracellular spaces; clinical meaning: Vd approximates total body water (0.6 L/kg in lean body mass), but glucose is rapidly taken up by cells.
Approximately 0.15-0.25 L/kg; approximates extracellular fluid volume; expands in hyperglycemia or fluid overload
Oral bioavailability is 100% for absorbed glucose; intravenous administration yields 100% bioavailability.
Intravenous: 100%; oral: not applicable (dextrose administered parenterally)
No specific GFR-based dosing adjustment; contraindicated in anuria or oliguria due to volume overload risk; use with caution in renal impairment.
No specific GFR-based dose adjustment; monitor serum glucose and electrolytes, especially in severe renal impairment (GFR <15 m L/min) due to risk of fluid overload and hyperglycemia.
No evidence for Child-Pugh-based adjustment; use with caution in severe hepatic impairment due to risk of fluid overload.
No specific Child-Pugh based adjustment; caution in severe hepatic impairment due to impaired gluconeogenesis, risk of hypoglycemia.
Intravenous infusion, 5-10 mg/kg/min dextrose (equivalent to 3-6 m L/kg/h of D10W) for maintenance; adjust based on glucose monitoring.
Neonates: 6-12 mg/kg/min as continuous IV infusion. Infants/children: 2-6 mg/kg/min for maintenance. Adjust rate based on glucose needs.
Caution due to risk of volume overload, heart failure, and electrolyte disturbances; start at lower rates and monitor closely.
Use with caution due to decreased renal function and higher risk of hyperglycemia and volume overload. Start at lower rates (50-100 m L/hour) and titrate based on response.
None
None. Dextrose 5% in plastic container does not have an FDA black box warning.
Hyperglycemia and hyperosmolar syndrome in patients with glucose intolerance,Risk of fluid overload, especially in patients with heart failure, renal impairment, or edema,Electrolyte disturbances (e.g., hypokalemia, hypophosphatemia) due to insulin-mediated cellular shifts,Thrombophlebitis if infused into small veins,Do not administer if solution is discolored or contains particulate matter
Risk of hyperglycemia in patients with diabetes mellitus or glucose intolerance,Monitor serum glucose levels closely in patients with impaired glucose tolerance,Avoid in patients with intracranial or intraspinal hemorrhage,Use with caution in patients with renal impairment due to risk of fluid overload,Do not administer if solution is cloudy or contains particles
Hyperglycemia (severe),Intracranial or intraspinal hemorrhage,Delirium tremens with dehydration,Hypersensitivity to dextrose or any component of the formulation,In patients with anuria, renal failure, or severe fluid overload
Hypersensitivity to dextrose or any components,Intracranial or intraspinal hemorrhage,Severe dehydration with hypernatremia,Diabetic coma with hyperglycemia
No direct food interactions. However, dietary intake of carbohydrates may need adjustment to prevent hyperglycemia. Monitor blood glucose levels if eating.
No significant food interactions; monitor dietary carbohydrate intake if hyperglycemia occurs.
No evidence of teratogenic effects in animal studies; not associated with congenital anomalies in humans regardless of trimester. Intravenous glucose crosses the placenta; maternal hyperglycemia may cause fetal hyperinsulinism and neonatal hypoglycemia. Use only if clearly needed.
Dextrose is an essential nutrient; no teratogenic risk at therapeutic doses. IV administration in pregnancy is safe; risk of maternal hyperglycemia may increase fetal macrosomia and neonatal hypoglycemia. No trimester-specific fetal malformation risk.
Endogenous glucose is a normal component of breast milk. Intravenous dextrose infusion increases maternal blood glucose, leading to increased milk glucose concentrations. No adverse effects expected. M/P ratio not applicable.
Dextrose is endogenous and safe during breastfeeding; no known adverse effects. M/P ratio not applicable as it is a physiologic sugar; no special precautions needed.
Increased plasma volume in pregnancy may require higher initial doses to achieve euglycemia. No standard dose adjustment; titrate based on maternal blood glucose monitoring.
No dose adjustment required for pregnancy. Monitor for fluid overload and hyperglycemia; consider decreased osmotic threshold. Maintain euglycemia; adjust infusion rate if gestational diabetes present.
Dextrose 10% in water (D10W) is a hypertonic solution (510 m Osm/L) that provides 340 kcal/L. Administer via central line to avoid phlebitis. Monitor serum glucose closely, especially in diabetics and critically ill patients. Use with caution in patients with intracranial hemorrhage as hyperglycemia may worsen outcomes. D10W is often used for neonatal hypoglycemia or as a maintenance fluid when higher dextrose concentrations are needed. Rapid infusion can cause hyperglycemia and osmotic diuresis.
Dextrose 5% in water is isotonic but becomes hypotonic after dextrose metabolism; monitor for hyperglycemia in stressed patients; avoid in patients with intracranial hemorrhage solutions; use with caution in renal impairment due to risk of fluid overload.
This solution provides sugar and fluids to prevent or treat low blood sugar.,Tell your doctor if you have diabetes, kidney disease, or heart failure.,Report any signs of infection at the IV site such as redness, swelling, or pain.,You may experience increased urination due to the sugar content.,Do not stop the infusion abruptly without medical advice.
Your IV bag contains sugar water to provide calories and hydration.,Tell your nurse if you feel increased thirst, frequent urination, or headache.,This solution may raise blood sugar, especially if you have diabetes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 10% IN PLASTIC CONTAINER vs DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 10% IN PLASTIC CONTAINER is a Intravenous Fluid that works by Intravenous dextrose provides a source of calories and water for hydration. Dextrose is metabolized to carbon dioxide and water, yielding energy (approximately 3.4 kcal/g). It also stimulates insulin secretion and promotes glycogen synthesis.. DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Fluid that works by Dextrose is a monosaccharide that provides a source of calories and fluid for parenteral nutrition. It increases blood glucose levels and is metabolized to carbon dioxide and water, providing energy. It also serves as a source of water for hydration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 10% IN PLASTIC CONTAINER and DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Fluid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 10% IN PLASTIC CONTAINER is: Intravenous infusion, 500-1000 m L (50-100 g dextrose) as a single dose, rate determined by clinical condition; typical maintenance 100-125 m L/h.. The standard adult dose of DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion: 500-1000 m L as needed based on fluid and caloric requirements. Typical rate: 100-200 m L/hour for maintenance. Maximum infusion rate: 0.5-0.8 g/kg/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 10% IN PLASTIC CONTAINER and DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 10% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenic effects in animal studies; not associated with congenital anomalies in humans regardless of trimester. Intravenous glucose crosses the placenta; maternal. DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose is an essential nutrient; no teratogenic risk at therapeutic doses. IV administration in pregnancy is safe; risk of maternal hyperglycemia may increase fetal macrosomia an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.